Previous studies showed increased tau plasma levels in patients with AD4–6, in a group of patients with AD and mild cognitive impairment (MCI) due to AD7 and in MCI due to AD4, but not in clinically classified MCI groups converting or not to AD during follow-up5, 6. This evidence concerns the gene MAPT and Alzheimer disease.